Study ID

Objective

Survival

Tumour response

Toxicity

Kokron 1977b

To compare symptomatic therapy vs Ifosfamide

MST: symptomatic treatment= 93 days versus 172 in Ifosfamide group. (Range= 11 to 544 vs 1 to 1096 respectively)

PR= 0% in control group vs 47% in Ifosfamide group

Haematological toxicity: 0% in control group vs 94.1% in Ifosfamide group

Kokron 1982

To compare symptomatic treatment vs Ifosfamide vs Ifosfamide+CCNU

Extensive disease: MST: symptomatic =56 days vs 134 Ifosfamide group vs 122 days Ifosfamide+CCNU. Grouped data: symptomatic: median= 161.5 (MST=208.4), ifosfamide: median=341.0 (MST=348.5), ifosfamide+CCNU: median=252.0 (MST=322.3)

Grouped data (extensive and limited disease): CR=1.9% in ifosfamide group; PR= 16.9% in ifosfmaide group and 13.2% in ifosfamide+CCNU group

Grouped data (extensive and limited disease): Leucopenia: 0% symptomatic group; 15% Ifosfamide; 15.8% I+CCNU. Vomiting and hair loss: 0% symptomatic group, 70% Ifosfamide; 68,4% I+CCNU. Other: 0% symptomatic group; 55% Ifosfamide; 52.6% I+CCNU